Improvement of cognitive functions by the acetylcholine releaser SM 21

Citation
C. Ghelardini et al., Improvement of cognitive functions by the acetylcholine releaser SM 21, DRUG DEV R, 47(3), 1999, pp. 118-126
Citations number
41
Categorie Soggetti
Pharmacology & Toxicology
Journal title
DRUG DEVELOPMENT RESEARCH
ISSN journal
02724391 → ACNP
Volume
47
Issue
3
Year of publication
1999
Pages
118 - 126
Database
ISI
SICI code
0272-4391(199907)47:3<118:IOCFBT>2.0.ZU;2-9
Abstract
The effect of administration of SM 21 on memory processes was evaluated in the mouse passive avoidance and in the rat social learning tests. SM 21 (10 -20 mg kg(-1) i.p.) prevented amnesia induced by scopolamine and dicyclomin e as tested by the mouse passive avoidance test and prevented memory disrup tion by AF-64A and benehexol ascertained by the rat passive avoidance test. Both SM 21 enantiomers were able to abolish dicyclomine-induced amnesia in mice. SM 21, starting from the dose of 10 mg kg(-1) i.p., antagonized the memory impairment produced by mecamylamine, baclofen, and diphenhydramine i n mice, as well as amnesia induced by diazepam in rats. SM 21, at doses ran ging between 10 and 30 mg kg(-1) i.p., prevented memo reduction in mice by hypoxia in the passive avoidance test. In the social learning test, SM 21 ( 10 mg kg p.) injected in adult rats reduced the duration of active explorat ion of a familiar partner in the second session of the test. SM 21 prevente d amnesia in both mice and rats comparable to that of the cholinesterase in hibitor physostigmine (0.2 mg kg(-1) i.p.), the M-1 selective agonist AF-10 2B (10 mg kg(-1) i.p.), and the nootropic drug piracetam (30 mg kg(-1) i.p. ). These results demonstrated the ability of SM 21 to modulate memory funct ions and suggests that SM 21 could be useful in the treatment of cognitive deficits. (C) 1999 Wiley-Liss, Inc.